Amylin Said To Be Attracting Several Big Pharma Suitors

May 2012
MondayMorning;5/21/2012, Vol. 20 Issue 21, p1
The article informs that Amylin Pharmaceuticals Inc., maker of diabetes drugs Bydureon and Byetta, is attracting suitors such as Pfizer Inc., AstraZeneca PLC and Sanofi SA, who have signed confidentiality agreements on the sale process of the firm. It has been informed that Amylin is seeking a buyer after it rejected an unsolicited offer from Bristol-Myers and first-round bids are expected in the next two weeks.


Related Articles

  • Icahn Says Amylin Should Pursue Sale Process.  // MondayMorning;4/9/2012, Vol. 20 Issue 15, p1 

    The article discusses demand for nomination of candidates to the diabetes drug maker's board by investor Carl Icahn to Amylin Pharmaceuticals Inc. It is mentioned that Amylin had turned down a 22 dollars per share offer from Bristol-Myers Co. worth a total of 3.5 billion dollars. The company...

  • Amylin Said to Draw First-Round Bids From Sanofi, Merck.  // MondayMorning;6/4/2012, Vol. 20 Issue 22, p1 

    The article informs that Sanofi SA and Merck & Co. have offered their purchsing proposal to Amylin Pharmaceuticals Inc., the diabetes drugmaker that has put itself up for sale, in an initial round of bidding. It has been informed that both companies have made bids of at least 25 dollar a share,...

  • EARNINGS ROUNDUP:.  // MondayMorning;4/25/2011, Vol. 19 Issue 16, p5 

    This section offers news briefs on earnings in the healthcare industry as of April 2011. Lincare Holdings Inc. increased it first-quarter profit by 6 percent earning as its revenue rose. Amylin Pharmaceuticals Inc. posted a first-quarter loss of about 37.3 million U.S. dollars or about 26 cents...

  • Amylin 'Back to Business' Following Contentious Vote.  // BioWorld Today;5/29/2009, Vol. 20 Issue 102, p3 

    The article reports that only two of Amylin Pharmaceuticals Inc.'s candidates backed by Easborune Capital Management and Carl Icahn gained seats on its board. However, 10 of the company's nominees were voted. It is assumed that if the preliminary results of the vote hold, the company is back in...

  • TOP STORIES.  // MondayMorning;9/22/2008, Vol. 16 Issue 37, p1 

    The article reports updates related to health industry in the U.S. Television advertisements showing medical devices pose an even greater risk to patients which lead to overutilization of impractical technologies than advertisements for drugs. Bristol-Myers Co. poses its willingness to drop its...

  • Other News To Note.  // BioWorld Today;4/5/2012, Vol. 23 Issue 66, p2 

    This section offers news briefs from the pharmaceutical biotechnology industry. A letter has been sent by activist shareholder Carl Icahn to Amylin Pharmaceuticals Inc. asserting his belief that a sale of the firm should be pursued by the company's board. An application to voluntary delist its...

  • Loose lips sink ships...and sales of fleets. Sloan, John // Fleet Owner Exclusive Insight;12/22/2014, p10 

    The article talks about the importance of a fleet owner to be cautious in sharing his plans of selling his fleet operations. Topics include the need for a merger and acquisition (M&A) advisor, the sharing of plans with confidential employees such as key executives and senior employees in...

  • Amylin Pharmaceuticals, Inc. SWOT Analysis.  // Amylin Pharmaceuticals, Inc. SWOT Analysis;Nov2007, p1 

    A company profile of Amylin Pharmaceuticals Inc., a company that engages in the discovery, development and commercialization of potential drug candidates for the treatment of diabetes and obesity, is presented. An overview of the company is given, along with key facts including contact...

  • Company Overview.  // Amylin Pharmaceuticals, Inc. SWOT Analysis;Nov2007, p4 

    An overview of Amylin Pharmaceuticals Inc., a company that engages in the discovery, development and commercialization of potential drug candidates for the treatment of diabetes and obesity, is presented. Data is included on revenues generated in fiscal year ended December 2006, as well as...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics